



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification 5 : C12N 15/38, A61K 39/245, 39/395 C12P 21/08, G01N 33/569 C12Q 1/68, C12N 5/20</p> <p style="text-align: center;">A1</p>		<p>(11) International Publication Number: WO 94/06912</p> <p>(43) International Publication Date: 31 March 1994 (31.03.94)</p>
<p>(21) International Application Number: PCT/EP93/02478</p> <p>(22) International Filing Date: 13 September 1993 (13.09.93)</p> <p>(30) Priority data: 92202797.4 14 September 1992 (14.09.92) EP (34) Countries for which the regional or international application was filed: NL et al.</p> <p>(71) Applicant (for all designated States except US): AKZO N.V. [NL/NL]; Velperweg 76, NL-6824 BM Arnhem (NL).</p> <p>(72) Inventor; and (75) Inventor/Applicant (for US only) : MIDDELDORP, Jaap, Michiel [NL/NL]; Staringstraat 151, NL-5343 GD Oss (NL).</p>		
<p>(74) Agent: HERMANS, Franciscus, G., M.; Postbus 20, NL-5340 BH Oss (NL).</p> <p>(81) Designated States: AU, CA, FI, JP, KR, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>		

(54) Title: EPSTEIN-BARR VIRUS PEPTIDES AND ANTIBODIES AGAINST THESE PEPTIDES

(57) Abstract

The invention relates to a peptide or fragment thereof which is immunochemically reactive with Epstein-Barr Virus (EBV) antibodies. A new monoclonal antibody directed to said peptide or fragment thereof is also part of the invention. The invention also relates to a method for the detection of EBV or anti-EBV antibodies in a test fluid and also to an immunochemical reagent comprising a peptide, a fragment or a polypeptide according to the invention and a test kit to be used when applying the said detection methods. Detection of EBV in a test fluid or tissue specimen using antibodies, monoclonal and polyclonal, directed to the said peptide, which have the characteristics of detecting both native and denatured intact, functional EBNA-1 protein is also part of said invention.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BN	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LJ	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TC	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

Title: Epstein-Barr Virus peptides and antibodies against these peptides.

5 The present invention relates to peptides immunochemically reactive with antibodies to the Epstein-Barr virus (EBV), monoclonal antibodies against these peptides, cell lines capable of producing monoclonal antibodies and anti-idiotype antibodies. The invention is further concerned
10 with immunological reagents and methods for the detection of EBV or anti-EBV antibodies.

15 EBV is an ubiquitous human herpes virus that was first discovered in association with the African (endemic or e) form of Burkitt's lymphoma (BL). Subsequently the virus was also found associated with nasopharyngeal carcinoma (NPC) and was shown to be the causative agent of
20 infectious mononucleosis (IM). Infection usually occurs during early childhood, generally resulting in a subclinical manifestation, occasionally with mild symptoms. Infection during adolescence or adulthood, however, can give rise to IM characterized by the presence of atypical
25 lymphocytes in the periphery. The bulk of these lymphocytes are T lymphocytes; however, included in their number are a small population of B lymphocytes infected by EBV. The infection of B lymphocytes may also be accomplished in vitro.
30 Such cells become transformed and proliferate indefinitely in culture and have been referred to as "immortalized", "latently infected" or "growth transformed". As far as is known, all individuals who become infected with EBV remain latently infected for life. This is reflected by the
35 lifelong continuous presence of small numbers of EBV-genome positive transformed B-cells among the

circulating peripheral blood lymphocytes and the continuous but periodic shedding of virus in the oropharynx.

5 In the vast majority of cases EBV infection results in a lymphoproliferative disease that may be temporarily debilitating, but is always benign and self-limiting. In certain immunosuppressed individuals, however, the result can be full-blown malignancy. This occurs in individuals who 10 are immuno-suppressed intentionally, particularly children receiving organ transplants who are treated with cyclosporine A, or opportunistically, as in the case with individuals infected with HIV, or genetically, as 15 in the case of affected males carrying the XLP (x-linked lymphoproliferative syndrome) gene. In these cases the resulting malignancies derive from the polyclonal proliferation of EBV-infected B cells. In addition, in such patients 20 uncontrolled epithelial replication of the virus is detectable in lesions of oral hairy leukoplakia. Thus, the immune response plays a central role in the control of EBV infection.

25 The presence of EBV in cells or tissues can be demonstrated by detection of the viral genome or demonstration of the EBNA-1 protein, the sole latency associated protein product that is universally expressed in EBV-infected cells.

30 As mentioned above EBV is a member of the herpesviruses. It possesses the following structural properties:

- The EBV genome consists of a linear double stranded DNA molecule (172,000 basepairs).
- The virion consists of a core (proteins and DNA), surrounded by an icosahedral capsid, and a membrane envelope enclosing the capsid. The

icosahedral capsid is built up of hexameric and pentameric capsomeres. The membrane envelope consists of a protein/lipid bilayer membrane with spikes on its outer surface. The space between the capsid shell and the envelope is filled with amorphous protein, called the tegument.

10 - Like all herpesviruses, EBV is capable of establishing a latent life-long infection in its host subsequent to primary infection. This latency represents a perfect balance between EBV and its human host, controlled by the host's immune system.

15 To date most biochemical and biological studies have been performed on three prototype strains of EBV, being B95-8 (transforming virus produced in a marmoset cell line), P3HR1 (non-transforming virus produced by a Burkitt's lymphoma tumor cell line) and Raji (latent virus in a Burkitt's lymphoma tumor cell line).

20 During the last few years the entire DNA
sequence of prototype virus strain, B95-8, has
been determined. Analysis of this sequence has
resulted in the identification of more than 80
open reading frames (Baer et al., 1984, Nature
25 310, p. 207-211).

The biology of EBV poses a special problem to investigators because its biological characteristics (latent infection) do not lend itself to the classic virus analysis. Furthermore, its cell and host range are effectively limited to human (and those of a few higher primates) B-lymphocytes and epithelial cells which are generally not amenable to culture in vitro. In addition, the absence of a fully permissive cell type, one in which the virus lytically replicates, has severely limited the ability to produce large amounts of the virus.

5 DNA molecules of B95-8, P3HR1- and Raji-isolates have been the prototypes for detailed restriction endonuclease mapping, and for cloning into Escherichia coli (E.coli) plasmids and in bacteriophage lambda, and for nucleotide sequencing.

10 The EBV-genome consists of a single double stranded DNA molecule build-up with unique and tandemly repeated DNA-elements. Each end of the DNA molecule contains multiple terminal sequences which permit covalently linking and circularization of the genome. In virus particles the EBV-genome is only detectable in a linear form. On the contrary, it exists as a circular episome inside the nucleus of latently infected 15 cells, and occasionally becomes integrated into the host cell chromosomes.

20 The internal repeat sequences, IR1 to IR4, separate the EBV-genome into 5 unique regions. The U2 and U3 regions vary extensively among different EBV isolates and, the former being almost entirely deleted in the P3HR-1 strain of EBV.

25 The nomenclature for EBV reading frames is based on their position in the virus genome. The names begins with the initials of the BamH1 or EcoR1 restriction fragment where expression begins. The third letter in the name is L or R, depending on whether the expression is leftward or rightward on the standard map. (So BLLF2 is the second leftward reading frame starting in BamH1 restriction fragment L.).

30 The serological classification of virus antigens in the production cycle of EBV is based on different fluorescence techniques.

35 Antigens specifically detected by means of the anti-complement immunofluorescence technique

in the nucleus of fixed latently infected B-cells (e.g. Raji-cells) are classified as Epstein-Barr nuclear antigens (EBNA).

Upon activation of viral gene expression by chemical or viral factors a class of early antigens (EA) is detected whose synthesis is not blocked by inhibition of viral DNA synthesis. Dependent on the type of fixative used (Methanol or Acetone) two distinct sets of EA are detectable, EA_R and EA_D. EA is detectable by indirect immunofluorescence in the cytoplasm and nucleus of induced cells. Following onset of viral DNA-synthesis (and depending upon it) virus structural proteins (VCA) are synthesized which are detectable by indirect immunofluorescence in the cytoplasm and nucleus of virus producer cells (e.g. P₃HR₁ cells). On the surface of viable infected cells, induced for virus production a set of antigens (MA) is detectable by indirect immunofluorescence. These antigens can also be found on the viral envelope and are important targets for virus neutralization.

Detection of EBV-specific antibodies in human sera can routinely be performed by serological techniques as described by Heule and Heule (Human Pathology, 5, 551-565, 1974).

Based upon biochemical and immunofluorescence data it is possible to distinguish five different classes of antigen molecules. The different viral polypeptides are designated by their molecular weight, and no common nomenclature has been established for all EBV-proteins in order to allow their unique description.

The five different groups of antigens are:

A. The group of antigens which are expressed during a state of latency (EBNAs and LMPs).

B. The group of antigens which are responsible for genome activation and initial induction of viral replication (IEA).

5 C. The group of antigens which are induced by IEA-gene products and which are required for replication of viral DNA; these antigens are mostly viral enzymes (EA).

10 D. The group of antigens which are structural components of the viral particle and are expressed late in the viral replication cycle (VCA), after initiation of viral DNA-synthesis.

15 E. The group of antigens which are expressed in the cell membrane of the infected cell (MA).

15

Epstein-Barr nuclear antigens (EBNA)

20 The Epstein Barr Nuclear Antigen 1 (EBNA-1), encoded in the BKRF 1, reading frame, is the only EBV-encoded protein expressed universally in all latently infected and tumor-associated cells in vivo and in vitro and forms an important target molecule for studying the mechanisms of DNA-replication and gene-activation.

25 EBNA-1 was identified by immunoblotting and radioimmunolectrophoresis in EBV-positive but not in three EBV-negative cell lines, utilizing four EBV-positive human sera in comparison with two EBV-negative human sera. The antigens identified had different molecular weights in the different cell lines analyzed, ranging from 30 65.000 to 73.000. A complement-fixing antigen had been partially purified more than 200 times and was found to co-purify with the 65-kDa EBNA 35 identified by immunoblotting. Since EBNA is defined by anti-complement immunofluorescence

(ACIF), it was suggested that the 65-kDa antigen was a major component of EBNA.

5 The EBNA gene was mapped by transfecting mouse cells with the cloned BamHI K restriction enzyme fragment of EBV DNA. The transfection of a mouse fibroblast line with this fragment, together with a dominant selectable marker, led to the stable expression of a nuclear antigen identified in ACIF with EBNA-positive, but not 10 EBNA-negative human sera. In a subsequent study it was found that Bam K-transfected cells expressed a 78-kDa polypeptide that co-migrated with the EBNA-1 polypeptide of B95-8 cells.

15 More recent studies have revealed an immunodominant region within the glycine-alanine repeat region, usually referred to as p62 or p107, which is strongly reactive with human sera. This gly-ala fragment however was shown to be contained within normal human proteins and was 20 found to be the target for auto-antibodies. In addition, further studies have revealed that especially IgM antibodies in the sera from patients with active CMV, HSV or Toxoplasma 25 infections occasionally show cross reactivity with this peptide. Furthermore a C-terminal fragment of 28 kD encoding AA 461-641 of EBNA-1, expresses in E.coli was shown to be reactive with human serum antibodies. Additional studies, thus 30 far, have failed to identify fragments of the EBNA-1 protein that can be used in replacing the intact EBNA-1 protein in diagnostics.

35 The molecular size of EBNA-1 can be used for strain identification (EBNO-typing) as the size of the gly-ala repeat region may show significant variation among individual viral strains.

EBNA-1 has been detected immunologically in cells of Burkitt lymphoma, Nasopharyngeal carcinoma and Reed-Sternberg cells as found in Hodgkin's Disease.

5 In addition, EBNA has also been detected in polyclonal lympho-proliferative lesions in transplants and AIDS-patients and is the earliest marker for identification of B-lymphocytes in cell culture.

10 Several functional domains have been identified on the EBNA-1 molecule, such as the DNA-binding (Ori-P) domain, nuclear localization domain, the transactivation domain, the DNA-looping domain and the dimerization domain. EBNA-15 exerts its DNA-binding function as a homo dimeric molecule.

20 At present EBV specific serodiagnosis is accomplished by rather subjective immunofluorescence tests. Progress to more simple and uniform diagnosis (e.g. ELISA) is hampered because bulk production and purification of viral antigens are not possible using standard virus producing cell lines.

25 The only way to achieve this would be to use alternatively prepared EBV antigen(s). These EBV antigens could be prepared with either genetic engineering techniques or synthetic peptide techniques.

30 For the development of a specific and sensitive method to enable a reliable diagnosis to be made in various phases of the infection with EBV it is of great importance to identify immuno-dominant viral proteins and epitopes 35 thereof.

The present invention provides peptides, immunochemically reactive with antibodies to the Epstein-Barr Virus, comprising at least part of the amino acid sequence as shown in SEQ ID No.: 1.

5

A peptide having the amino acid sequence as shown in SEQ ID No:1 and fragments thereof are therefore part of the present invention.

10

The peptides according to the invention are found to be particularly suitable for use in a diagnostic method for the determination of the presence of EBV or EBV-antibodies in a sample. Moreover, a peptide according to the invention may be used in suitable pharmaceutical dosage forms in the treatment of an EBV-related disease. The preparation of vaccines thus obtained which contain a peptide or fragment thereof as active ingredients, is known to one skilled in the art.

15

In contrast to the natural EBV, the peptides according to the invention have the great advantage that these are of a safe non-infectious origin.

20

The invention also comprises fragments of said peptides which are still immunochemically reactive with antibodies to the Epstein-Barr Virus.

25

The specific characteristics of the said peptide region of EBNA-1 make it accessible to antibodies in both native and denatured configurations of the EBNA-1 protein.

30

The term "peptide" as used herein refers to a molecular chain of amino acids with a biological activity, and does not refer to a specific length of the product. Thus inter alia,

proteins, fusion-proteins or -peptides oligopeptides and polypeptides are included. If required peptides according to the invention can be modified in vivo or in vitro, for example by glycosylation, amidation, carboxylation or phosphorylation. Functional variants like, for example, acid addition salts, amides, esters, and specifically C-terminal esters, and N-acyl derivatives of the peptides according to the invention are therefore also considered part of the present invention. It will be understood that for the particular proteins or polypeptides embraced herein, natural variations can also exist. These variations may be demonstrated by (an) amino acid difference(s) in the overall sequence or by deletions, substitutions, insertions, inversions or additions of (an) amino acid(s) in said sequence. Amino acid substitutions from which can be expected that they do not essentially alter biological and immunological activities, have been described. Amino acid replacements between related amino acids or replacements which have occurred frequently in evolution are, inter alia Ser/Ala, Ser/Gly, Asp/Gly, Asp/Asn, Ile/Val (see Dayhof, M.D., *Atlas of protein sequence and structure*, Nat. Biomed. Res. Found., Washington D.C., 1978, vol. 5, suppl. 3). Based on this information Lipman and Pearson developed a method for rapid and sensitive protein comparison (Science 227, 1435-1441, 1985) and determining the functional similarity between homologous proteins.

The term "fragment" as used herein means an amino acid sequence comprising a subsequence of a peptide of the invention. Said fragment is a peptide having one or more immunogenic

5 determinants of the EBNA-1 protein. Fragments can inter alia be produced by enzymatic cleavage of precursor molecules, using restriction endonucleases for the DNA and proteases for the polypeptides. Other methods include chemical synthesis of the fragments or the expression of peptide fragments by DNA fragments.

10 Suitable immunogenic fragments of a peptide according to the invention containing (an) epitope(s) can be found by means of the method described in Patent Application WO 86/06487, Geysen, H.M. et al. (Proc. Natl. Acad. Sci. 81, 3998-4002, 1984), Geysen, H.M. et al. (J. Immunol. Meth. 102, 259-274, 1987) based on the 15 so-called pepscan method, wherein a series of partially overlapping peptides corresponding with partial sequences of the complete polypeptide under consideration, are synthesized and their reactivity with antibodies is investigated.

20 In addition, a number of regions of the peptides can be designated epitopes on the basis of theoretical considerations, although the predictive value of these theoretical considerations is limited. The determination of 25 these regions is based on a combination of the hydrophilicity criteria according to Hopp and Woods (Proc. Natl. Acad. Sci. 78, 3824-3828, 1981) and the secondary structure aspects according to Chou and Fasman (Advances in 30 Enzymology 47, 45-148, 1987).

Preferred peptides according to the invention are peptides comprising at least one of the sequences as depicted in SEQ ID No.: 2 to 6.

35 Peptides having the sequences as shown in SEQ ID No. 2-4 are fragments of the peptide with

5 amino acid sequence as shown in SEQ ID No.1 and correspond to amino acids no. 268-391, 395-425 and 419-449 of the EBNA-1 sequence respectively. A peptide having the amino acid sequence as shown in SEQ ID No.: 5 is a peptide comprising a combination of fragments (SEQ ID No.'s 2-4) of the sequence of SEQ ID No.: 1.

10 The preparation of the peptides or fragments thereof according to the invention is effected by means of one of the known organic chemical methods for peptide synthesis or with the aid of recombinant DNA techniques.

15 The organic chemical methods for peptide synthesis are considered to include the coupling of the required amino acids by means of a condensation reaction, either in homogeneous phase or with the aid of a so-called solid phase.

20 The condensation reaction can be carried out as follows:

25 a) condensation of a compound (amino acid, peptide) with a free carboxyl group and protected other reactive groups with a compound (amino acid, peptide) with a free amino group and protected other reactive groups, in the presence of a condensation agent;

30 b) condensation of a compound (amino acid, peptide) with an activated carboxyl group and free or protected other reaction groups with a compound (amino acid, peptide) with a free amino group and free or protected other reactive groups.

35 Activation of the carboxyl group can take place, inter alia, by converting the carboxyl group to an acid halide, azide, anhydride, imidazolide or an activated ester, such as the N-

hydroxy-succinimide, N-hydroxy-benzotriazole or p-nitrophenyl ester.

5 The most common methods for the above condensation reactions are: the carbodiimide method, the azide method, the mixed anhydride method and the method using activated esters, such as described in *The Peptides, Analysis, Synthesis, Biology* Vol. 1-3 (Ed. Gross, E. and Meienhofer, J.) 1979, 1980, 1981 (Academic Press, Inc.).

10

15 Preparation of suitable fragments of above-mentioned peptides according to the invention using the "solid phase" is for instance described in *J. Amer. Chem. Soc.* 85, 2149 (1963) and *Int. J. Peptide Protein Res.* 35, 161-214 (1990). The coupling of the amino acids of the peptide to be prepared usually starts from the carboxyl end side. For this method a solid phase is needed on which there are reactive groups or on which such groups can be introduced. This can be, for example, a copolymer of benzene and divinylbenzene with reactive chloromethyl groups, or a polymeric solid phase rendered reactive with hydroxymethyl or amine-function.

20

25

30 A particulary suitable solid phase is, for example, the p-alkoxybenzyl alcohol resin (4-hydroxy-methyl-phenoxy-methyl-copolystrene-1% divinylbenzene resin), described by Wang (1974) *J. Am. Chem. Soc.* 95, 1328. After synthesis the peptides can be split from this solid phase under mild conditions.

35 After synthesis of the desired amino acid sequence, detaching of the peptide from the resin follows, for example, with trifluoromethane-sulphonic acid or with methanesulphonic acid

5 dissolved in trifluoroacetic acid. The peptide can also be removed from the carrier by transesterification with a lower alcohol, preferably methanol or ethanol, in which case a lower alkyl ester of the peptide is formed directly. Likewise, splitting with the aid of ammonia gives the amide of a peptide according to the invention.

10 The reactive groups which may not participate in the condensation reaction are, as stated, effectively protected by groups which can be removed again very easily by hydrolysis with the aid of acid, base or reduction. Thus, a 15 carboxyl group can be effectively protected by, for example, esterification with methanol, ethanol, tertiary butanol, benzyl alcohol or p-nitrobenzyl alcohol and amines linked to solid support.

20 Groups which can effectively protect an amino group are the ethoxycarbonyl, benzyloxycarbonyl, t-butoxy-carbonyl (t-boc) or p-methoxy-benzyloxycarbonyl group, or an acid 25 group derived from a sulphonic acid, such as the benzene-sulphonyl or p-toluene-sulphonyl group, but other groups can also be used, such as substituted or unsubstituted aryl or aralkyl 30 groups, for example benzyl and triphenylmethyl, or groups such as ortho-nitrophenyl-sulphenyl and 2-benzoyl-1-methyl-vinyl. A particularly suitable α -amino-protective group is, for example, the base-sensitive 9-fluorenyl-methoxycarbonyl (Fmoc) 35 group [Carpino & Han (1970) J. Amer. Chem. Soc. 92, 5748].

5 A more extensive account of possible protecting groups can be found in *The Peptides, Analysis, Synthesis, Biology, Vol. 1 - 9* (Eds. Gross, Udenfriend and Meienhofer) 1979 - 1987 (Academic Press, Inc.).

10 It is necessary also to protect the ϵ -amino group of lysine and advisable for the guanidine group of arginine. Customary protective groups in this connection are a Boc-group for lysine and a Pmc- or Pms- or Mbs-group or Mtr-group for arginine.

15 The protective groups can be split off by various conventional methods, depending on the nature of the particular group, for example with the aid of trifluoroacetic acid or by mild reduction, for example with hydrogen and a catalyst, such as palladium, or with HBr in glacial acetic acid.

20 As already indicated above, the peptides according to the invention can likewise be prepared with the aid of recombinant DNA techniques. This possibility is of importance particularly when the peptide is incorporated in a repeating sequence ("in tandem") or when the peptide can be prepared as a constituent of a (much larger) protein or polypeptide or as a fusion protein with, for example, (part of) β -galactosidase. This type of peptides therefore likewise falls within the scope of the invention. For this purpose, as a constituent of a recombinant DNA, a nucleic acid sequence is used which codes for a peptide according to the invention and which, furthermore, is substantially free from nucleic acid segments.

which in the naturally occurring EBV genome flank the nucleic acid sequence indicated above.

5 This latter method involves the preparation of the desired peptide by means of bringing to expression a recombinant polynucleotide with a nucleic acid sequence which is coding for one or more of the peptides in question in a suitable micro-organism as host.

10 A nucleic acid sequence encoding a peptide according to the present invention can be ligated to various replication effecting DNA sequences with which it is not associated or linked in nature resulting in a so called recombinant vector molecule which can be used for the transformation of a suitable host. Useful recombinant vector molecules, are preferably derived from, for example plasmids, 15 bacteriophages, cosmids or viruses.

20 Specific vectors or cloning vehicles which can be used to clone nucleic acid sequences are known in the art and include inter alia plasmid vectors such as pBR322, the various pUC, pGEM and Bluescript plasmids, bacteriophages, e.g. kgt-Wes, Charon 28 and the M13 derived phages or viral vectors such as SV40, adenovirus or polyoma virus (see also Rodriguez, R.L. and D.T. Denhardt, ed., *Vectors: A survey of molecular cloning vectors and their uses*, Butterworths, 1988; Lenstra, J.A. et al., *Arch. Virol.* 110, 1-24, 1990). The methods to be used for the construction of a recombinant vector molecule are known to those of ordinarily skill in the art and are inter alia set forth in Maniatis, T. et al. 25 (Molecular Cloning A Laboratory Manual, second edition; Cold Spring Harbor Laboratory, 1989). 30 35

For example, the insertion of the nucleic acid sequence encoding a peptide according to the invention into a cloning vector can easily be achieved when both the genes and the desired cloning vehicle have been cut with the same restriction enzyme(s) as complementary DNA termini are thereby produced.

The recombinant vector molecules may additionally contain one or more marker activities that may be used to select for desired transformants, such as ampicillin and tetracycline resistance in pBR322, as for example ampicillin resistance and α -peptide of β -galactosidase in pUC8.

It should, of course, be understood that the nucleotide sequences inserted at the selected site of the cloning vector may include only a fragment of the complete nucleic acid sequence encoding for the peptides according to the invention as long as the transformed host will produce a polypeptide having at least one or more immunogenic determinants.

Antibodies, directed to a peptide according to the invention are also part of the present invention.

The peptides or fragments thereof prepared and described above can be used to produce antibodies, both polyclonal and monoclonal. Monoclonal antibodies directed against peptides according to the invention can be readily produced by one skilled in the art.

Prior to the present invention there has been no report of antibodies generated against this specific peptide fragment of EBNA-1. No one

skilled in the art till this moment will know the availability of the epitopes to bind antibodies.

The monoclonal antibodies according to the present invention, therefore, provide a new means for the diagnosis of EBV infection.

Preferred antibodies according to the invention are monoclonal antibody having the same reactivity with EBNA-1 as monoclonal antibodies produced by the hybridoma cell line deposited with the European Collection of Animal Cell Cultures (ECACC), Porton Down (UK), under deposit No. 92071613.

A new (monoclonal) antibodies according to the invention, which are designated as EBNA.OT1x, was generated by immunizing mice with Baculovirus-derived EBNA-1 protein lacking the Gly-Ala repeat region. With deletion fragments from EBNA-1 expressed in E.Coli the binding epitope of EBNA.OT1x was located within position 430-438 close to the putative nuclear localization signal (sequence as depicted in SEQ ID No.:6). EBNA.OT1x has been used in immunoprecipitation studies. EBNA.OT1x also binds to denatured EBNA-1 as used in Western blot studies and immuno fluorescence on fixed permeabilized cells (FACS) using indirect detection techniques, and reacts with EBNA-1 from a wide variety of virus strains and virus-infected target cells. EBNA.OT1x binds to EBNA-1 from multiple EBV-isolates and can be used in immunohistochemical staining in a variety of human tumor tissues.

Immortalized cell lines capable of excreting monoclonal antibodies according to the invention are also part of the present invention.

5 The preparation of cell lines producing monoclonal antibodies may occur by, for example, by the Kohler and Milstein technique (Kohler and Milstein devised the techniques that resulted in
10 the formation monoclonal antibody-producing hybridomas (G. Kohler and C. Milstein, 1975, Nature 256:495-497; 1976, Eur. J. Immunol. 6:511-519)), transformation with Epstein-Barr Virus, or a direct transformation technique of B-lymphocytes with oncogenic DNA, or a direct fusion of human B-lymphocytes with a fusion partner being either a human or a mouse-human hybrid myeloma cell line, or a direct fusion of an EBV-transformed B cell line with said myeloma
15 cell lines.

20 A preferred cell line according to the invention is the cell line deposited at the European Collection of Animal Cell Cultures, Porton Down (UK) under deposit No. 92071613.

25 This hybridoma cell line was produced by the fusion of a myeloma cell with a lymphocyte derived from a mouse previously inoculated with an EBNA-1 peptide according to the invention. (A peptide with the amino acid sequence as shown in SEQ ID No.: 5.)

30 The invention further comprises the use of antibodies to said peptide in immunological and biochemical methods aiming to detect the full length protein in a test fluid or tissue specimen.

35 Up till now detection of EBNA-1 in EBV infected cells was performed by using the anti-complement immunofluorescence (ACIF) technique using human sera as the anti EBNA-1 antibody

5 source. Indirect immunofluorescence techniques failed to detect EBNA-1 binding antibodies in human sera. ACIF is complicated by the extra complement-incubation step and the instability of the complement itself. In addition false-positive and -negative reactions are frequently encountered when reagents used for ACIF are not properly used.

10 The EBNA.OT1x antibody on the other hand eliminates these problems and allows the sensitive detection of EBNA-1 in a variety of EBV-infected cells by means of indirect immunofluorescence.

15 the presence of EBNA-1 in the cell nucleus is the hallmark of latent EBV-infection in cells, both *in vivo* and *in vitro*.

20 EBNA.OTx1 is capable of penetrating into cells thus allowing the detection of EBNA-1 intracellularly in EBV-infected cells: The EBV.OT1x antibody can be applied in Fluorescence Activated Cell Sorter (FACS) analysis of nuclear staining in EBV-infected cells permeabilized by buffered formalin-acetone (BFA) fixation as described by Slaper-Cortenbach et al. (Blood, 72, 25 1639-1644, 1988). This method has the advantage of being simple and rapid and allows the detection of EBV-infected B-lymphocytes cultured *in vitro*. This technology may also be applied to the detection and monitoring of EBV-associated 30 lymphoproliferative diseases and lymphoma.

35 Antibodies, both monoclonal and polyclonal, directed against peptides according to the invention are very suitable in diagnosis and immunocytochemistry for detection *in situ* in tissue specimen, while those antibodies which are

neutralizing are very useful in passive immunotherapy.

5 The antibodies according to the invention may also be used in EBNO-typing of different EBV isolates. As mentioned before, EBV isolates (strains) can be characterized by the molecular weight of the EBNA-1 molecule produced, due to the extensive variation in length of the glycine-alanine repeat region in this protein. Unlike 10 previously described reagents, being mainly human sera, the EBNA.OT1x monoclonal antibody is a stable and reproducible reagent, detecting a binding epitope which is highly conserved within 15 the EBV-family, which is highly suitable for EBNO-typing of EBV strains.

20 Part of the invention is also the "humanizing" of the monoclonal antibodies in question. Techniques for raising the "humanized" 25 monoclonal antibodies are known in the art.

25 Especially monoclonal antibodies may be used to raise anti-idiotype antibodies. Techniques for raising anti-idiotype antibodies are known in the art.

30 Anti-idiotype antibodies reactive with the monoclonal antibodies according to the invention, as described above, are part of the present invention.

35 Anti-idiotype antibodies are antibodies directed to the variable part of immunoglobulins. A sub-population of anti-idiotype antibodies is known as "anti-idiotype B" or "internal images". These anti-idiotype B antibodies have either a structural or a three dimensional resemblance

with the antigen (Uytdehaag, F.G.C.M. et al. Immunol. Rev; 90; 93-113; 1986). This type of anti-idiotype antibodies is widely used as a vaccine against infectious diseases in animal models (Hiernaux J.R.; Infect. Immun.; 56; 1407-1413; 1988, Kennedy, R.C. et al.; Science 232; 220-223; 1986). For use in assays the anti-idiotype antibodies can be raised in large amounts.

Techniques for raising anti-idiotype antibodies are known in the art. For example, anti-idiotype antibodies according to the invention can be obtained by immunizing BALB/c mice with monoclonal antibodies, coupled to KLH with glutaraldehyde according to standard literature procedures, mixed with Freund's complete adjuvant. The spleen cells of these mice can be immortalized and the thus obtained hybridomas can be screened for anti-idiotype antibody production. Screening of the hybridomas can be performed, for example, by binding monoclonal antibodies according to the invention to a solid phase (wells of microtiter plates) and incubating the solid phase with culture supernatant of growing hybridomas. An EBV peptide coupled to Horse Radish Peroxidase (HRP) can be added. The presence of anti-idiotype antibodies in culture supernatant will then be indicated by inhibition of the binding of this peptide conjugate to the monoclonal antibodies coated on the solid phase.

Anti-idiotype antibodies can be used for instance for inhibiting the binding of human and/or animal EBV-antigen in an immuno assay using EBV-antibodies. Alternatively anti-idiotype

antibodies can be used as a mimicking agent of the immunochemical reagent mentioned hereunder.

5 Said anti-idiotype antibodies are also useful for diagnosis and treatment of EBV, as well as for the elucidation of important epitopic regions of EBV-antigens.

10 An immunochemical reagent comprising one or more peptides or antibodies according to the invention is also part of the present invention.

15 The term "immunochemical reagent" according to the invention usually consists of one or more peptides according to the invention and a suitable support or a labelling substance.

20 Supports which can be used are, for example, the inner wall of a microtest well or a cuvette, a tube or capillary, a membrane, filter, test strip or the surface of a particle such as, for example, a latex particle, an erythrocyte, a dye sol, a metal sol or metal compound as sol particle, a carrier protein such as BSA or KLH.

25 Labelling substances which can be used are, inter alia, a radioactive isotope, a fluorescent compound, an enzyme, a dye sol, metal sol or metal compound as sol particle.

30 In a method for the detection of antibodies directed against EBV in a sample, an immunochemical reagent according to the invention is brought into contact with the sample. After which, the presence of immune complexes formed between the peptide and antibodies in the sample is detected and by this detection the presence of EBV antibodies in the sample is known and can be 35 determined quantitatively.

5 Depending on the nature and further characteristics of the immunochemical reagent the immunochemical reaction that takes place is a so called sandwich reaction, an agglutination reaction, a competition reaction or an inhibition reaction.

10 For the detection of EBV in a sample an immunochemical reagent according to the invention, containing one or more peptides according to the invention, can be brought into contact with the sample and anti-EBV after which the presence of immune complexes formed can be detected and, from this, the presence of EBV in a sample can be determined.

15 A particularly suitable method for the detection of EBV in a sample is based on a competition reaction between a peptide according to the invention provided with a labelling substance and an EBV antigen (present in the sample) whereby the peptide and the antigen are competing with the antibody directed against EBV attached to a solid support.

20 25 The invention further comprises a method for the detection of Epstein-Barr virus in a sample characterized in that an antibody according to the invention is brought into contact with a sample whereafter the presence of immune complexes formed is detected which is a measure for the presence of Epstein-Barr Virus in the sample.

30 35 A test kit according to the invention comprises as an essential constituent an immunochemical reagent as described above. Carrying out a sandwich reaction, for the

5 detection of EBV antibodies the test kit may comprise, for example, the peptide according to the invention coated to a solid support, for example the inner wall of a microtest well, and either a labelled peptide according to the invention or a labelled anti-antibody.

For carrying out a competition reaction, the test kit may comprise a peptide according to the invention coated to a solid support, and a labelled antibody directed against EBV preferably a monoclonal antibody directed against said peptide.

15 In an agglutination reaction the test kit comprises an immunochemical reagent which may comprise a peptide according to the invention coated to particles or sols.

Another embodiment of a test kit is, for example, the use of a labelled peptide according to the invention as immunochemical reagent in a competition reaction with an EBV antigen to be detected for a binding site on the antibody directed against EBV, which is coated to a solid support.

25

Brief description of the figures:

Figure 1: results of pepscan analysis with human sera. Indicated on the X-axis are the relative starting positions of each individual 12-mer peptide on the EBNA-1 sequence, such that "0" represents the 12-mer peptide starting at AA 348 and so forth. Indicated on the Y-axis are relative absorbance units at 450 nm.

35 Line no.1 represents the immuno reactivity
of an EBV negative human serum towards the
respective 12-mer peptides.

Line no.2-6 represent the immuno reactivity of EBV positive human sera towards the 12-mer peptides.

5 Figure 2: ELISA reactivity (optical density at 450 nm) of 46 human serum samples tested for IgG-reactivity against selected synthetic peptides derived from the EBNA-1 protein.

10 Δ indicates sera negative by standard serological analysis

\square indicates sera positive by standard serological analysis

X indicates sera positive on immunoblot for EBNA-1 only.

15 $\square, *$ indicates sera with no detectable anti EBNA-1 antibodies by immunoblot but otherwise (i.e. anti-VCA) EBV-seropositive.

A = peptide 348-369

B = peptide 368-387

20 C = peptide 394-420

D = peptide 424-452

E = peptide Gly-Ala

F = combi-peptide

G = EBNA-1 Baculo

25 Figure 3: results of PEPSCAN analysis using mouse monoclonal antibodies and rabbit sera. Indicated on the X-axis are the relative starting positions of each individual 12-mer peptide on the EBNA-1 sequence, such that "0" represents the 12-mer peptide starting at AA 348 and so forth. Indicated on the Y-axis are relative absorbance units at 450 nm.

30 35 Line 1 represents the reactivity of an anti EBV VCA p40 monoclonal (EBV.OT41A) towards the EBNA-1 derived peptides, used as negative control.

Line 2-4 represent the reactivity of the anti EBNA-1 mouse monoclonal antibody EBNA.OT1x in different concentrations (5 μ g/ml, 10ng/ml and 1ng/ml respectively).

5 Line 5 represents the reactivity of non-immunized rabbit serum.

Line 6 indicates the reactivity of rabbit serum immunized with recombinant EBNA-1.

10 Figure 4: Indirect immunofluorescence for the detection of EBNA-1 in EBV-infected cells using the EBNA.OT1x monoclonal antibody. A: X50-7 cells, latently infected with EBV. B: HH514.c16 cells induced for EBV expression mixed 1:1 with 15 EBV negative BJAB cells.

Figure 5: FACS analysis of intranuclear EBNA-1 staining in a variety of lymphoid cells and cell lines:

20 A: Analysis of EBV negative Jurkat cells,
B: Analysis of EBV positive human Burkitt lymphoma cells (Daudi),
C: Analysis of peripheral blood lymphocytes from an EBV seronegative donor.
25 D: Analysis of polyclonal EBV transformed human B-lymphocytes,
E and F: Analysis of established cloned B-cells (EBV-positive).

30 The Y-axis represents the number of cells counted, while the X-axis represents the fluorescence intensity per cell.

The dotted line in each graph represents the control antibody (anti HIV-p24).

35 Figure 6:
A: Results of EBNA typing of different EBV strains with monoclonal antibody EBNA.OT1x.

B: Results of EBNO typing of different EBV strains with human serum.

- 1 = BJAB
- 2 = CR+B95.8
- 5 3 = CR+QIMR-WIL
- 4 = PB-LCL
- 5 = CR+BL72
- 6 = CR+Mwika
- 7 = CR+AG876
- 10 8 = CR+Ambobi
- 9 = CR+WW1
- 10 = CR+WW2

15 The invention is further exemplified by the following examples:

EXAMPLE 1:

20 Localisation of immunoreactive domains by PEPSCAN.

25 Peptides with a length of 12 amino acids (AA) and an overlap of 11 AA of the AA sequence of ORF BKRF₁, positions 348-470, were synthesized by automated solid phase peptide synthesis onto chemically activated polyethylene pins as originally described by Geijzen et al. (P.N.A.S., 30 USA, 83, 3998-4002, 1984).

35 The immunoreactivity for EBV-specific antibodies was determined as described by Middeldorp and Meloen (J.Virol. Meth. 21, 147-159, 1988). The results of such a PEPSCAN analysis for 6 individual human sera is shown in figure 1.

From this figure it can be seen that reactive regions are found with 12-mer peptides starting at AA20-31, 43-65, 74-85 and 90-98, representing AA 372-381, 391-413, 422-433 and 5 438-446 on the EBNA-1 sequence respectively. Similar reactivities were found with additional sets of human sera. No significant reaction was found when using EBV-seronegative sera, as indicated by line no.1 in figure 1.

EXAMPLE 2:Selection of immunoreactive synthetic peptides.

5

The selection of synthetic peptides, derived from the BKRF_1 -encoded EBNA-1 protein by computer analysis and PEPSCAN, and the analysis of the immunoreactivity of these peptides with 10 normal human donor sera is outlined below.

Synthetic peptides were made by standard solid phase synthesis using t-BOC chemistry. Peptides from the AA 348-470 fragment of the 15 BKRF_1 -encoded EBNA-1 protein were selected either on the basis of predicted high antigenicity using the computer program "antigenic index" developed by Jameson and Wolf (CABIOS 4, 181-186, 1988) [peptides 348-369 and 20 368-387 were selected on this basis] or on the basis of functional high antigen reactivity in PEPSCAN as described in Example 1 [Peptides 394-420 and 424-452 were selected on this basis].

In addition, a combi-peptide was made which 25 represents a combination of the four most reactive domains (B-E in figure 1) identified by PEPSCAN. The sequence of this combi peptide is depicted in SEQ ID. No.: 5.

30 For control purposes the P107 glycine-alanine co-polymer peptide was used as described by A.Linde et al. (J.Infect. Dis., 161, 903-910, 1990). This peptide represents a previously published immunoreactive domain of the EBNA-1 35 protein. In addition, a recombinant form of the EBNA-1 protein, containing the full length EBNA-1 sequence except the glycine-alanine domain was

used. This recombinant protein was purified from rec. Baculovirus-infected insect cells as described by Frappier and O'Donnell (J.Biol.Chem., 266, 7819-7826, 1991).

5

The peptides and proteins described above were coated onto the solid phase; the wells of polystyrene microtiter plates, at 1 μ g per ml. in 0,05 M NaHCO₃ buffer of pH 9.6 overnight at 4°C. 10 After washing twice with phosphate-buffered saline at pH 7.4 (PBS) the wells were filled with 100 μ l of human serum, diluted 1:100 in PBS containing 0.05% Tween-20 (PBST) and incubated for 1 hour at 37 °C. After three PBST washes HRP-labelled sheep anti-human IgG antibodies were 15 added at the appropriate dilution in PBST and incubated for 1 hour at 37 °C. After three washes with PBST, bound enzyme activity was detected using TMB as substrate. The reaction was stopped 20 at 30 minutes by adding 100 μ l 1M H₂SO₄. The absorbance was measured at 450 nm using a Multiscan photometer. Sera were tested for the presence of EBV -antibodies using standard immunofluorescence serology or immunoblot 25 analysis as described by Middeldorp and Herbrink (J.Virol.Meth., 21, 133-146, 1988).

Figure 2 shows the results of ELISA experiments using the respective EBNA-1 reagents 30 coated on the solid phase and a panel of 36 EBV-seropositive sera (□) and 10 EBV-seronegative sera (Δ). From this figure it can be seen that sera that contained no detectable antibodies to EBNA-1 by immunoblot were negative with all EBNA 35 derived peptides except with the combi-peptide and the Baculo-derived EBNA-1 protein.

From the above described experiments it is apparent that computer predictions based upon the "antigenic index" program have no predictive value with respect to the immunogenecity towards sera from naturally infected individuals as almost all sera are negative with the highly charged peptides 348-369 and 368-387.

Peptides selected on the basis of PEPSCAN show good reactivity with 80-90% of the sera for peptides 394-420 (combination of domains B+C of figure 1) and 424-452 (combination of domain D+E). Surprisingly the combi-peptide shows positive reactivity with 100% of the EBV-seropositive sera tested. EBV seronegative sera show no reactivity with the combi-peptide, whereas one such serum showed a false-positive reaction with the baculo derived EBNA-1 protein.

EXAMPLE 3:

Localization of immunoreactive epitopes on EBNA-1 using mouse monoclonal antibodies..

5

The procedure used for the localization of immunoreactive epitopes on EBNA-1 fragment 348-470 using mouse monoclonal antibodies and rabbit sera are as already described in Example 1 for the localization of epitopes using human sera.

15 Mouse antibody-binding to the pin-bound peptides was measured using sheep anti-mouse IgG labelled with peroxidase, whereas rabbit antibody-binding was measured using sheep anti-rabbit labelled with peroxidase.

Results are shown in figure 3. From these results it can be seen that monoclonal antibodies not specifically directed at EBNA proteins (anti EBV VCA-p40 or non immunized rabbit serum) do not react with any of the EBNA-1 peptides tested.

25 Mouse monoclonal EBNA.OT1x recognizes an epitope at AA420-445 when used at high concentration, which narrows down with dilution of the antibody to an epitope at AA430-438. The rabbit serum 121-3, raised by immunization with the Baculo derived EBNA-1 protein, recognizes three epitopes in the EBNA-1 region analysed.

30

EXAMPLE 4:

Indirect immunofluorescence for the detection of EBNA-1 in EBV-infected cells, using EBNA.OT1x.

5 A. X50-7 cells, latently infected with EBV, were fixed with acetone-methanol (1:1) on 12 well glass slides stained with EBNA.OT1x antibody at 2 μ g/ml in phosphate buffered saline pH 7.4 (PBS) containing 1% Bovine Serum Albumin (BSA) for 1 hour at 37°C. After four PBS washes rabbit anti-mouse IgG labelled with fluorescein isothiocyanate (FITC) was added, diluted in PBS + 1% BSA and incubated for 1 hour at 37°C. After 10 four additional PBS washes goat anti-rabbit labelled with FITC was added and incubated as above. Finally, after four PBS washes, the slides were covered with mounting fluid (50% glycerol pH9.0) and sealed with a cover slip.

15 B: HH514.c16 cells, a superinducible clone from the EBV-producer cell line P₃HR₁, induced for EBV-expression using TPA and butyrate for 6 days were mixed 1:1 with EBV-negative BJAB cells 20 and fixed onto 12-well glass slides using 100% acetone. EBNA.OT1x was added as described under A and after four washes with PBS goat anti-mouse F(ab)-FITC was added, appropriately diluted in PBS+1%BSA and incubated at 37°C for 1 hour. After 25 four PBS washes the slides were covered with mounting fluid and sealed with a cover slip.

30 All incubations (in A and B) were performed in a humidified chamber to prevent evaporation of reagents. Fluorescent staining was visualised using a Zeiss Axioscope fluorescence microscope (magnification 400x).

35 The results as depicted in figure 4A and 4B show a characteristic nuclear EBNA staining pattern in 100% of the cells latently infected with EBV, such as found for the X50-7 cell line

shown in panel A, when using a double FITC-staining technique, to increase sensitivity. Results in panel B show the specificity of the staining by EBNA.OT1x as most of the small EBV-negative BJAB cells show no staining at all, whereas the large EBV-producer cells show a strong nuclear staining pattern in about 50% of the cells.

10

EXAMPLE 5:

15

Fluorescence Activated Cell Sorter (FACS) analysis.

20

25

30

35

EBV-negative human T-cells (Jurkat), EBV-positive human Burkitt-lymphoma cells (Daudi), polyclonal EBV-transformed human B-lymphocytes, established cloned B-cell lines or peripheral blood lymphocytes from an EBV-seronegative donor were fixed according to the BFA-method and incubated with EBNA.OT1x (1 μ g/ml) in PBS plus 1% BSA at a cell concentration of 2×10^6 /ml at 4°C. After washing with PBS three times, the cells were incubated with goat anti-mouse IgG-F(ab)₂ labelled with FITC, appropriately diluted in PBS-BSA. After another wash step 10^4 cells were analysed with a flow cytometer (FACSCAN, Becton-Dickinson). As a negative control each experiment was paralleled by a separate incubation of the same cells with a non-relevant monoclonal antibody (anti HIV-p24, IgG).

The results of the above described experiments are given in figure 5A-F. The dotted line in each graph represent the control monoclonal antibody whereas the continuous line shows the results obtained for the EBNA.OT1x

monoclonal antibody. From these experiments it can be concluded that, using BFA as the fixation method as described by Slaper-Cortenbach et al. (Blood, 72, 1639-1644, 1988), EBNA.OT1x is 5 capable of penetrating into cells thus allowing the detection of EBNA-1 intracellularly in EBV-infected cells.

10

EXAMPLE 6:Immunoblot staining and EBNO typing.

15

The detection of denatured EBNA-1 by means of immunoblot staining and its application in EBNO-typing of different EBV isolates using the EBNA.OT1x antibody according to the invention is illustrated below.

20

In figure 6 an example is shown of an analysis with a variety of different EBV strains as present in B-cell lines obtained from different geographical regions in the world.

25

In each line of figure 6A and 6B a sample of 5×10^4 EBV-infected or control (BJAB) cells, denatured by boiling in reducing SDS-PAGE sample buffer, was subjected to standard SDS-PAGE and blotting to nitro cellulose.

30

Panel A (figure 6A) shows the EBNA-staining using EBNA.OT1x monoclonal antibody whereas panel B shows the same analysis using a human serum mono-specific for EBNA-1 staining (i.e. not reactive with additional EBNA molecules). In spite of the differences in intensity, the staining patterns for both reagents are

identical, showing the molecular weight variation among individual EBV-isolates. BJAB represents an EBV-negative cell line extract.

5 From these experiments it can be concluded that EBNA.OT1x reacts with multiple EBV-strains and can be used as reagent in EBNO-typing.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

5

(i) APPLICANT:

- (A) NAME: Akzo N.V.
- (B) STREET: Velperweg 76
- (C) CITY: Arnhem
- 10 (E) COUNTRY: The Netherlands
- (F) POSTAL CODE (ZIP): 6824 BM

10

15

(ii) TITLE OF INVENTION: Epstein-Barr
Virus peptides and antibodies against these
peptides.

(iii) NUMBER OF SEQUENCES: 6

(iv) COMPUTER READABLE FORM:

20

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0,
Version #1.25 (EPO)

25

(vi) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: EP 92202797.4
- (B) FILING DATE: 14-SEP-1992

30

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

35

- (A) LENGTH: 123 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

	Gly	Gly	Ser	Gly	Gly	Arg	Arg	Gly	Arg	Gly
1					5				10	
10	Arg	Glu	Arg	Ala	Arg	Gly	Gly	Ser	Arg	Glu
					15				20	
	Arg	Ala	Arg	Gly	Arg	Gly	Arg	Gly	Arg	Gly
					25				30	
15	Glu	Lys	Arg	Pro	Arg	Ser	Pro	Ser	Ser	Gln
					35				40	
	Ser	Ser	Ser	Ser	Gly	Ser	Pro	Pro	Arg	Arg
					45				50	
	Pro	Pro	Pro	Gly	Arg	Arg	Pro	Phe	Phe	His
					55				60	
20	Pro	Val	Gly	Glu	Ala	Asp	Tyr	Phe	Glu	Tyr
					65				70	
	His	Gln	Glu	Gly	Gly	Pro	Asp	Gly	Glu	Pro
					75				80	
	Asp	Val	Pro	Pro	Gly	Ala	Ile	Glu	Gln	Gly
25					85				90	
	Pro	Ala	Asp	Asp	Pro	Gly	Glu	Gly	Pro	Ser
					95				100	
	Thr	Gly	Pro	Arg	Gly	Gln	Gly	Asp	Gly	Gly
					105				110	
30	Arg	Arg	Lys	Lys	Gly	Gly	Trp	Phe	Gly	Lys
					115				120	
	His	Arg	Gly							

(2) INFORMATION FOR SEQ ID NO: 2:

35

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 amino acids

40

- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

5 (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

10

Arg	Ala	Arg	Gly	Arg	Gly	Arg	Gly	Arg	Gly
1				5				10	
Glu	Lys	Arg	Pro	Arg	Ser	Pro	Ser	Ser	Gln
						15			20

15

Ser Ser Ser Ser

(2) INFORMATION FOR SEQ ID NO: 3:

20

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 31 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

25

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

30

Pro	Arg	Arg	Pro	Pro	Pro	Gly	Arg	Arg	Pro
1				5				10	
Phe	Phe	His	Pro	Val	Gly	Glu	Ala	Asp	Tyr
						15		20	
Phe	Glu	Tyr	His	Gln	Glu	Gly	Gly	Pro	Asp
						25		30	

Gly

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

5

- (A) LENGTH: 31 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

10

(ii) MOLECULE TYPE: peptide

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

20

Gln	Glu	Gly	Gly	Pro	Asp	Gly	Glu	Pro	Asp
1				5				10	
Val	Pro	Pro	Gly	Ala	Ile	Glu	Gln	Gly	Pro
					15				20
Ala	Asp	Asp	Pro	Gly	Glu	Gly	Pro	Ser	Thr
					25				30
Gly									

25

(2) INFORMATION FOR SEQ ID NO: 5:

30

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 58 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

35

(ii) MOLECULE TYPE: peptide

-2

Pro Pro Arg Arg Pro Pro Pro Gly Arg Arg
1 5 10

Pro Phe Phe His Pro Val Gly Glu Ala Asp
15 20

5 Tyr Phe Glu Tyr His Gln Glu Cys Cys Asp
25 30

Gly Glu Pro Asp Val Pro Pro Gly Ala Ile
35 40

Glu Gln Gly Pro Ala Asp Asp Pro Gly Glu
10 45 50

Gly Pro Ser Thr Gly Pro Arg Gly

(2) INFORMATION FOR SEQ ID NO: 6:

15 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: peptide

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Pro Asp Val Pro Pro Gly Ala Ile Glu Gln
1 5 10

Gly Pro

30

Claims

- 5 1. Peptide, immunochemically reactive with antibodies to the Epstein-Barr Virus, comprising at least part of the amino acid sequence as shown in SEQ ID No.: 1.
- 10 2. Peptide according to claim 1, comprising one or more of the amino acid sequences as shown in SEQ ID No.: 2 to 6.
- 15 3. Antibody directed against a peptide according to claim 1 or 2.
- 20 4. Antibody according to claim 3 ,the antibody being a monoclonal antibody.
- 25 5. Monoclonal antibody having the same reactivity with EBNA-1 as monoclonal antibodies produced by the hybridoma cell line deposited with the European Collection of Animal Cell Cultures (ECACC), Porton Down (UK), under deposit No. 92071613.
- 30 6. Immortalized cell line capable of producing monoclonal antibodies according to claim 5.
- 35 7. Immortalized cell line deposited with the European Collection of Animal Cell Cultures (ECACC), Porton Down (UK), under deposit No. 92071613.
8. Anti-idiotypic antibody reactive with the antibody according to any of claims 3-5.

9. Immunochemical reagent comprising a peptide according to claim 1 or 2 bound to a suitable carrier or label.

5 10. Immunochemical reagent comprising an antibody according to any of claims 3-5, bound to a suitable carrier or label.

10 11. A method for detection of EBV in a sample which comprises contacting said sample with an antibody according to any of claims 3-5 whereafter the presence of immune complexes formed is detected and from this the presence of EBV in the sample is determined.

15 20 12. Method for the detection of antibodies directed against Epstein-Barr Virus in a test fluid, characterized in that an immunochemical reagent according to claim 9 is brought into contact with the test fluid and the presence of immune complexes formed in the test fluid is detected.

25 30 13. Method for the detection of Epstein-Barr Virus in a test fluid characterized in that an immunochemical reagent according to claim 9 is brought into contact with test fluid and antibodies directed Epstein-Barr Virus, whereafter the presence of immune complexes formed is detected and from this the presence of Epstein-Barr Virus in the test fluid is determined.

35 14. Test kit for carrying out the method according to any of claims 11-13.

FIGURE 1






FIGURE 2



3/9

FIGURE 3




BEST AVAILABLE COPY

WO 94/06912

PCT/EP93/02478

4/9


FIGURE 4





SUBSTITUTE SHEET

5/9



FIGURE 5



6/9



7/9




8/9

FIGURE 6

a 1 2 3 4 5 6 7 8 9 10
205-

116-

97-



66-

45-

9/9

b 1 2 3 4 5 6 7 8 9 10
205-

116-

97-



66-

45-

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/EP 93/02478

A. CLASSIFICATION OF SUBJECT MATTER

IPC 5 C12N15/38 A61K39/245 A61K39/395 C12P21/08 G01N33/569
C12Q1/68 C12N5/20

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 C12N A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GENE. vol. 43, no. 1-2 , 1986 , AMSTERDAM NL pages 41 - 50 HAMMERSKJÖLD ET AL. 'High-level expression of the Epstein-Barr virus EBNA1 protein in CV1 cells and human lymphoid cells using a SV40 late replacement vector' see the whole document ---	1-4
P,X	EP,A,0 508 427 (MOCHIDA PHARMACEUTICAL CO.) 14 October 1992 see the whole document ---	1-4
A	WO,A,86 01210 (SCRIPPS CLINIC AND RESEARCH FOUNDATION) 27 February 1986 see the whole document -----	1-14

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *B* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *A* document member of the same patent family

Date of the actual completion of the international search

17 December 1993

Date of mailing of the international search report

01-02- 1994

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Cupido, M

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 93/02478

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-0508427	14-10-92	JP-A- AU-A-	4310861 1480992	02-11-92 15-10-92
-----	-----	-----	-----	-----
WO-A-8601210	27-02-86	US-A- AU-B- AU-A- CA-A- EP-A- JP-T- US-A- US-E- US-A-	4654419 585529 4721085 1292839 0191813 62500027 5116725 RE33897 5122448	31-03-87 22-06-89 07-03-86 03-12-91 27-08-86 08-01-87 26-05-92 21-04-92 16-06-92
-----	-----	-----	-----	-----